$BLCO

Munsch Frederick sold $888K of BLCO

Munsch Frederick (SVP, Controller and CAO) sold 52,900 shares of Bausch & Lomb Corp (BLCO) at $16.78 ($0.89M total) on 2026-08-10.

Original reporting
SEC EDGAR · Munsch Frederick
Published Aug 12, 2026, 11:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 11:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BLCO
Neutral
medium confidence
Mentioned
$BLCO
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLCONeutralLow
01

Why it matters

The disclosure provides a concrete datapoint on insider selling activity (shares, price, total value, post-transaction holdings) but no new operational or strategic information.

02

Market read

Traders may briefly reassess sentiment around BLCO due to insider selling, but the filing alone is unlikely to drive a durable repricing.

03

What to watch

No 10b5-1 plan is cited, but the filing also lacks motivation, option exercises, or other concurrent insider activity that would help interpret intent.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-12, sale dated 2026-08-10

Background

The article is an SEC Form 4 insider transaction disclosure for Bausch & Lomb Corp.

Company-level read

Ticker impact

$BLCONeutralMedium confidence
Context

Bausch & Lomb insider Munsch Frederick sold 52,900 shares at $16.7800 on 2026-08-10, totaling $887,662, per Form 4.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment.

Evidence & confidence

The filing discloses transaction size and price but provides no new company-specific operating or regulatory information. Insider sales are common and often not predictive, especially without additional context.

Market effects

Minimal. Insider sale does not change sector fundamentals for eye care/pharma peers based on the provided text.

None indicated.

None indicated.

Counterpoint

The sale could be driven by diversification, taxes, or pre-existing personal liquidity needs, so it may not signal reduced confidence in BLCO’s outlook.

Key entities

  • Bausch & Lomb Corp

    Subject of the Form 4 insider transaction disclosure.

  • Munsch Frederick

    SVP, Controller and CAO who sold shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BLCOMed

Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance

Bausch + Lomb (BLCO) and Bausch Health (BHC) announced Thomas J. Appio as interim CEO of Bausch + Lomb, replacing Brent Saunders. Appio will retain his role as Bausch Health CEO. The companies expect to raise full-year 2026 adjusted EBITDA guidance based on preliminary third-quarter results, with details to be provided on Oct. 28.

$BLCOLow

Bausch + Lomb Advances Oral Dry AMD Therapy BL1243 Following FDA Meeting

Bausch + Lomb (BLCO) reported progress in developing BL1243, an oral treatment for dry age-related macular degeneration (AMD), following a constructive FDA meeting. The FDA supported the proposed initial study design, which will assess the drug's safety and behavior in the body. If successful, BL1243 could offer a new treatment option for dry AMD patients. The company plans to initiate clinical trials in 2027.